This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis, cost-utility analysis
Study objective
To evaluate the cost-effectiveness of using the percentage of carbohydrate-deficient transferrin (%CDT) test to screen, in primary care, for unhealthy alcohol use, in men and women, aged 18 to 100 years.
Interventions
Four screening strategies were examined. These were the Alcohol Use Disorders Identification Test (AUDIT) questionnaire only, %CDT test only; AUDIT followed by %CDT test, and no screening (case finding).
Location/setting
USA/primary care.
Methods

Analytical approach:
The analysis was based on a decision-analytic model, for the short-term (screening, assessment, and treatment), followed by a Markov model, with six alcohol-related health states, for a lifetime horizon. The authors stated that they adapted a societal perspective.
Effectiveness data:
The effectiveness data were derived from published studies identified through MEDLINE search, expert opinion, and relevant documents. Only bibliographical details were given for the sources of effectiveness data. The key clinical endpoints were the transitions between alcohol-related states (non-drinker, safe drinker, at-risk drinker, alcohol abuser, alcohol dependent, and alcohol dependent in recovery), with each scenario and age. The transition rate from the nondrinker state and the transition rate into the dependent state were estimated by adjusting the other transition rates until the proportions entering those states were consistent with published data.
Monetary benefit and utility valuations:
The utility values for alcohol-related health states were derived from a published study, which used the standard gamble method to elicit the preferences. The utility values for non-drinkers and safe drinkers were based on published estimates.
Measure of benefit:
Quality-adjusted life-years (QALYs) and life-years gained were the summary measures of benefit. Future QALYs and life-years were discounted at an annual rate of 3%.
